either azithromycin or a quinolone for LD treatment in hospitalized patients [25] .
Using a large national database, we sought to determine current antibiotic use for adults hospitalized with LD and to evaluate the association of different treatment regimens-specifically, azithromycin and quinolones-with hospital mortality, morbidity, and cost.
METHODS
We conducted a retrospective analysis of patients discharged from hospitals in the Premier Perspectives database from 1 July 2008 through 30 June 2013. Premier Perspectives is the largest drug utilization database in the United States including approximately 20% of all US hospital discharges from >400 hospitals [27] . Premier, Inc (Charlotte, North Carolina and Washington, D.C.) provides audit feedback to participating hospitals. Participation is voluntary and hospitals pay for the service.
Available data on hospital characteristics include number of beds, region (Midwest, Northeast, South, and West of the United States), community (rural vs urban), and teaching status. Demographic data include age, race (white, black, Hispanic, other), sex, marital status, and primary source of payment for medical services. Chronic medical conditions were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and diagnostic-related groups as described by Elixhauser et al [28] [29] [30] . Severity of acute illness was quantified by predicted probability of hospital mortality calculated using a strategy created and validated by Rothberg et al for patients with pneumonia in the Premier Perspectives database [31] . The validity of this scoring scheme was reassessed in our cohort using both the area under the receiver operating curve and the correlation of expected vs observed mortality by severity score decile as in the original Rothberg et al validation (Supplementary Figure 1) .
Our primary cohort consisted of adults (≥18 years) admitted with a diagnosis of LD (as determined by ICD-9 code 482.84: pneumonia due to Legionnaires' disease). We excluded children because LD is exceedingly rare in this age group [3, 32, 33] . We validated the use of ICD-9 coding to identify patients with LD (Supplementary Data and Supplementary Figure 2 ). Because we hypothesized that antibiotic choice would matter more for patients with more severe disease, we also evaluated a second cohort of patients with the highest severity of LD illness. These patients were a priori defined to meet at least 1 of the following criteria: required intensive care unit (ICU) admission, required mechanical ventilation (identified using daily service and supply charges as described by Lindenauer et al [34] ), or had a predicted probability of hospital mortality in the top quartile for all LD patients.
Our primary outcome was hospital mortality. Development of Clostridium difficile colitis (ICD-9 code 008.45 [35] ), hospital length of stay (LOS), hospital costs, and discharge destination for survivors (eg, home, facility) were secondary outcomes.
Antibiotic Data and Grouping
We used detailed pharmacy charges to identify antibiotic choice, dose, and duration. All systemic antibiotics were evaluated. An antibiotic was considered part of the primary regimen if the patient (1) received that antibiotic on the first 2 days of LD-appropriate antibiotic therapy (days 1 and 2 or days 1 and 3 for patients in whom daily dosing was not given) and (2) received it for at least 75% of the total days of antibiotic therapy. Additionally, if a patient received only 1 day of therapy, any antibiotic given on that day was considered primary. In this way, both the impact of early antibiotic and overall treatment choices were captured. Patients were classified as having received a combination regimen if >1 antibiotic met the criteria to be a primary antibiotic.
We then stratified patients under 2 paradigms of primary antibiotic usage: (1) azithromycin vs any quinolone and (2) by individual antibiotic regimen-including class and dose. This second categorization included the following groups: azithromycin only, high-dose levofloxacin only (750 mg daily; including patients who also received a second quinolone, n = 4 [1% of group]), standard-dose quinolone only, azithromycin plus quinolone, LD antibiotics with no primary (azithromycin and/or a quinolone was given, but neither met criteria to be considered a primary medication), pneumonia antibiotics with no LD antibiotics (at least 1 dose of a non-LD antibacterial/antifungal/antiviral/antimycobacterial was given and no doses of azithromycin or quinolones were given), and no pneumonia antibiotics (no antibiotics effective against pneumonia were given).
Statistical Analyses
We summarized antibiotic usage and patient-and hospital-level characteristics, stratified by primary antibiotic regimen using standard statistics.
Primary Analysis: Azithromycin Versus Quinolones
We used a propensity score-matching strategy for the comparison of LD patients who received azithromycin vs any quinolone. First, we created a propensity score for the probability that each patient would receive a quinolone (vs azithromycin) using multivariable logistic regression including all available demographic, comorbidity, severity of illness, and hospital-level data as independent variables [36] [37] [38] . This propensity score is a probabilistic measure that reflects the propensity for each patient, based on other characteristics, to receive a quinolone. To allow for nonlinear relationships, continuous variables were included in the multivariable model as 4-knot cubic splines [39] . The success of the propensity score was determined by its ability to balance independent covariates between patients who received a quinolone and those who received azithromycin; this balance was assessed using standard mean differences [40] .
We then matched patients who received a quinolone to those who received azithromycin but had a similar propensity to receive a quinolone. Matching was performed, after randomly ordering patients, using the "psmatch2" algorithm [41] in Stata 13 (StataCorp, College Station, Texas) with 1-to-1 nearest-neighbor matching without replacement and with maximal caliper distance of 25% of the standard deviation of all propensity scores. Additionally, exact matching was used for covariates for which the propensity score did not achieve appropriate balance.
Hospital mortality and all secondary outcomes were compared between groups using χ 2 test and Student t test as appropriate. We repeated the propensity score generation and matchbased analysis for the subgroup of patients with highest severity of illness. We performed a post hoc sensitivity analysis including only patients who remained in the hospital for at least 3 days and who received either azithromycin or a quinolone for at least 3 days; this analysis excluded patients in whom treatment exposure was potentially too short to impact hospital mortality.
Comparison Across All Antibiotic Groups Propensity score matching has only been robustly developed for comparison between 2 groups. To compare outcomes across all identified antibiotic regimens, therefore, we used multivariate logistic and linear regression modeling. The independent variable of interest was the individual antibiotic regimen-including class and dose. Additional independent variables were the same as those used for the propensity score model detailed previously. Continuous dependent variables with skewed distributions (LOS and cost) were log-transformed for inclusion in the models. These analyses were also repeated for the cohort of highest severity of LD patients. All statistical analyses were performed using Stata 13 and SAS 9.4 (SAS Institute Inc, Cary, North Carolina), and Microsoft Excel (Microsoft, Redmond, Washington). Institutional review board exemption was obtained from Albert Einstein College of Medicine (number 2013-2602).
RESULTS
We identified 3152 adults with LD admitted to 437 US hospitals over 5 years. Of all LD patients, 64.6% received LD treatment using a primary antibiotic strategy whereas an additional 30.0% received treatment effective against LD but without a clear primary antibiotic strategy ( Figure 1 ). Quinolones alone were used in 28.8% (10.7% of whole cohort received highdose levofloxacin), whereas azithromycin alone was used in 34.0% of patients. Only 1.8% of patients received a primary antibiotic strategy of azithromycin plus a quinolone.
Azithromycin Versus Quinolones
Baseline characteristics of patients receiving quinolones and azithromycin were largely similar (Table 1) ; there were small Figure 1 . In-hospital treatment strategies used for patients with Legionella pneumonia. *Including 4 patients who also received a second quinolone (1% of group). differences in sex (38.8% of patients in quinolone group were female vs 33.9% in azithromycin group; P = .025) and hospital discharge year (P = .041). Patients receiving quinolones had slightly higher predicted probabilities of hospital mortality (9.0% ± 12.1% for quinolone group vs 7.9% ± 11.8% for azithromycin group; P = .044) and more commonly required ICU/ stepdown/telemetry monitoring, mechanical ventilation, central venous catheterization, arterial or venous blood gases, and vasopressor medications. Hospital mortality was similar between groups (unmatched mortality: 6.6% vs 6.4%; P = .87). After propensity matching, 813 quinolone/azithromycin pairs were created that were well balanced on all measured patient-and hospital-level variables (Table 1) . There was no difference in propensity-matched mortality (6.3% for quinolones vs 6.5% for azithromycin; P = .84; Table 2 ). LOS (10.0 ± 11.7 days vs 9.5 ± 9.0 days; P = .34), rates of development of C. difficile colitis (1.4% vs 2.1%; P = .25), and costs ($24 286 ± $43 559 vs $22 463 ± $28 863; P = .32) were similar between groups. Fewer survivors were discharged home among patients treated with quinolones (70.7% vs 75.5%; P = .035); however, the difference in discharges to a skilled nursing or long-term acute care facility was small (21.9% for quinolones vs 20.4% for azithromycin).
Among patients with the highest severity of illness, there was no difference in any of the outcomes examined for patients treated with quinolones vs azithromycin ( Table 2) . The results were similar when the cohort was restricted to patients who remained in the hospital and obtained either azithromycin or a quinolone in the hospital for at least 3 days (Table 3) .
Comparison Across All Antibiotic Groups
Baseline characteristics differed significantly among patients treated with each antibiotic regimen (Table 4) . Patients receiving high-dose levofloxacin and combination azithromycin plus a quinolone were younger and had fewer comorbidities. Patients who received standard-dose quinolones only and those treated with LD antibiotics without a primary strategy had the highest probability of hospital mortality. Additionally, patients treated with LD antibiotics without a primary strategy required ICU admission more often than patients in other treatment groups. Patients who received no antibiotics effective against LD in the hospital-both those who received pneumonia antibiotics and those who did not-had lower probabilities of hospital mortality and markedly lower rates of ICU/stepdown/telemetry admission.
Adjusted hospital mortality was similar across all treatment strategy groups with the exception that receiving LD antibiotics without a primary strategy compared with azithromycin as a primary strategy was associated with a reduced hospital mortality (Table 5) . Hospital LOS and cost were increased for patients treated with LD antibiotics without a clear primary regimen, whereas LOS was shorter for patients treated with high-dose levofloxacin. The small group of patients who received no antibiotics effective against LD or any other pneumonia while hospitalized had significantly shorter adjusted LOS and total cost. There was no difference in C. difficile development across antibiotic treatment regimens. Among patients with the highest severity of LD disease, no difference was found in adjusted mortality rate. Adjusted LOS and total hospital cost again differed by treatment strategy.
DISCUSSION
Consistent with current guidelines [25] and expert opinion [26] , the vast majority (94%) of patients hospitalized in the United States with LD are currently treated with azithromycin and/or a quinolone; in about two-thirds of cases the in-hospital regimen is clearly dominated by 1 agent (34.0% azithromycin, 28.8% a quinolone, and 1.8% a combination of the two). We found no association between treatment based on a primary strategy of azithromycin compared with a primary strategy of a quinolone and hospital mortality, development of C. difficile colitis, hospital LOS, or cost of the hospitalization in unadjusted or adjusted analyses.
The finding of no difference in hospital mortality with treatment using either azithromycin or a quinolone could either be due to a true lack of association between antibiotic choice and mortality or residual confounding from systematic use of 1 antibiotic regimen for sicker patients. However, the characteristics of patients who received azithromycin and quinolones were remarkably similar, even before propensity matching, suggesting that systematic differences in the patients treated with different antibiotics are unlikely to explain the findings. A randomized trial comparing azithromycin and quinolones would more definitively answer this question. Given the relative rarity of LD, such a trial is unlikely to be feasible or practical [42] [43] [44] .
Although prior studies identify quinolone therapy as a significant risk factor for the development of C. difficile colitis [45] [46] [47] [48] [49] , we did not find any association. The low prevalence of C. difficile infection in our cohort (<2%), however, may have limited our power to detect a true difference. Similarly, we found no association between use of azithromycin or a quinolone and cost for the hospitalization. Although the cost of each quinolone dose was higher ($27.0 ± $32.0 vs $19.4 ± $19.5 for an azithromycin dose; P < .001), this cost represents a very small portion of hospital cost (<0.1%). The lack of association of azithromycin vs quinolones on other outcomes that could greatly impact cost (survival, LOS, complications such as C. difficile) resulted in the cost for the hospitalizations being similar. This finding is consistent with an outpatient study of community-acquired pneumonia in which use of a macrolide was associated with the same costs as use of levofloxacin [50] . In comparing all treatment strategies, we found that patients who received LD antibiotics without a primary strategy had lower hospital mortality but longer LOS and higher costs of care. A possible explanation for these findings is that these patients represent a group in whom therapy was adjusted when clinical improvement was suboptimal. These patients remained in the hospital longer-accruing higher costs but achieving better outcomes-as a result of their clinicians' willingness to try new antibiotics when those first used were failing. The small group of patients who received no antibiotics effective against pneumonia had shorter LOS and lower costs than other patients. The shorter LOS and lower cost implies that these patients were likely either (1) too well at the time of LD diagnosis to require inpatient treatment (and were discharged to potentially receive outpatient antibiotics) and/or (2) very ill and died prior to being able to receive a dose of appropriate pneumonia therapy. Given the absence of a clear association with mortality, this group is likely comprised of a combination of the two. Notably, this group had a relatively low predicted mortality and, conversely, a relatively higher adjusted odds of inhospital death, potentially highlighting the importance of early initiation of antibiotics for LD patients to improve survival.
The strengths of this study stem, first, from its large size (3152 patients hospitalized with LD, of whom 1981 received azithromycin or a quinolone as primary therapy). Taken together, the 7 published studies to date comparing the clinical efficacy of a quinolone and a macrolide for the treatment of LD are comprised of <900 patients [18] [19] [20] [21] [22] [23] [24] . Second, our findings of no association between azithromycin vs a quinolone and hospital mortality was robust across subgroup and sensitivity analyses. There are limitations to our study, however. Despite similar baseline characteristics, patients were not randomized to 1 treatment regimen vs another; thus the possibility of residual confounding remains. Additionally, our cohort was defined by ICD-9 codes for LD; although we have demonstrated high sensitivity and specificity for this identification method in a single center, a small and potentially unique subset of patients may have been misclassified. Also, our analyses were limited to the interventions and events occurring during the index hospitalization for each patient. It is likely that many survivors were discharged from the hospital to complete antibiotic courses. Knowing the specific regimens used in the posthospital setting would help inform this topic. Finally, the sample sizes that we had for some individual regimens (in particular, more aggressive regimens-high-dose levofloxacin or combination azithromycin plus a quinolone) were very small; thus, the absence of an association of these with mortality is likely due, at least in part, to limited statistical power. Similarly, differences in hospital LOS and cost noted for these small groups must be interpreted with caution. Abbreviations: CI, confidence interval; LD, Legionnaires' disease. a Natural logarithm of length of stay and cost was used for models.
b AIDS and connective tissue diseases were omitted as independent variables because patients with each of these had no Clostridium difficile; arterial/venous blood gas was additionally similarly omitted from model for the sickest cohort. c One percent received another quinolone in addition to levofloxacin 750 mg.
d Azithromycin + quinolone, pneumonia antibiotics but no LD antibiotics, and no pneumonia treatment had no cases of C. difficile.
Consistent with current guidelines, our results support the use of either azithromycin or a quinolone as in-hospital treatment for patients with LD [25] . Local determinants-such as formulary preference or antimicrobial stewardship programs-may appropriately impact decisions. Additionally, we cannot say from our results whether there is value (or possibly harm) in using combination treatment. For certain patients, this may be an appropriate option. A sizeable prospective randomized trial to identify an optimal treatment regimen would be ideal. In its absence, however, additional analyses using real-world data can further inform this topic. Most notably, understanding the association of therapy duration (inpatient and outpatient) on clinically relevant outcomes might be very helpful in allowing clinicians to shorten treatment courses.
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